Scinai Immunotherapeutics Ltd. (SCNI)
Summary
Scinai Immunotherapeutics Ltd. (SCNI) Q2 2024 Earnings Call Transcript
Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI ) Q2 2024 Results Conference Call August 20, 2024 11:00 AM ET Company Participants Liat Halpert - Head of Business Development Amir Reichman - CEO Liat Halpert Good morning, everyone.
Scinai Immunotherapeutics stock surges 55% on breakthrough psoriasis treatment results
Scinai Immunotherapeutics Ltd (NASDAQ: SCNI) unveiled promising preclinical outcomes for its innovative anti IL-17A/F antibody fragment (NanoAb) aimed at treating mild to moderate plaque psoriasis.
Why Is Scinai Immunotherapeutics (SCNI) Stock Up 56% Today?
Scinai Immunotherapeutics (NASDAQ: SCNI ) stock is taking off on Monday after the development stage biopharmaceutical company announced results from an early study. Scinai Immunotherapeutics revealed results from an in-vivo preclinical study of anti IL-17A/F VHH antibody fragment NanoAb.
Scinai Immunotherapeutics Ltd. (SCNI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Scinai Immunotherapeutics Ltd. ever had a stock split?
Scinai Immunotherapeutics Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Amir Reichman CEO | NASDAQ (CM) Exchange | 09073Q204 CUSIP |
| IL Country | 31 Employees | - Last Dividend | 21 May 2024 Last Split | - IPO Date |
Overview
Scinai Immunotherapeutics Ltd., previously known as BiondVax Pharmaceuticals Ltd., is a biopharmaceutical company in its development stage, rooted in Israel. With a primary focus on the research, creation, and commercialization of medical products aimed at the prevention and treatment of infectious and autoimmune diseases, alongside other health conditions, Scinai Immunotherapeutics stands at the forefront of innovation in medical therapy. The company’s strategic partnerships, including licensing and collaboration agreement with esteemed institutions such as the Max Planck Society and University Medical Center Göttingen, underscore its commitment to advancing healthcare solutions, particularly in the fight against COVID-19. Since its establishment in 2003 and rebranding in September 2023, Scinai Immunotherapeutics has solidified its presence in the biopharmaceutical industry, with its headquarters based in Jerusalem, Israel.
Products and Services
The offerings of Scinai Immunotherapeutics Ltd. are marked by innovative approaches to tackle health challenges, prominently featuring:
- COVID-19 NanoAb: In the arena of infectious diseases, the company has made significant strides with its licensing and collaboration agreement with the Max Planck Society and University Medical Center Göttingen. This partnership underpins the development and commercialization of a nanosized antibody (NanoAb) targeting COVID-19. Leveraging nanotechnology, this novel therapeutic approach aims to enhance treatment efficacy and patient outcomes in the battle against the pandemic.
- NanoAbs for Various Disease Indications: Beyond COVID-19, Scinai Immunotherapeutics extends its nanotechnology-based solutions to address a broader spectrum of diseases. The company’s developments include NanoAbs tailored for various other disease indications, signifying a versatile and forward-thinking approach to immunotherapy. These advancements underscore the company’s commitment to diversifying its product portfolio and addressing a range of health conditions with cutting-edge medical innovations.
